For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?

Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?

Answer from: Medical Oncologist at Academic Institution

This is a very relevant question as we are treating more patients with neoadjuvant endocrine therapy in the COVID-19 era. Ki67 and other markers can respond promptly after neoadjuvant hormonal therapy, it may take longer than 4 months to judge the clinical and histological response. If this is a pat...

Comments

Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
Agree with @Saundra S. Buys. It can take 6 months ...

Please select the option that best describes you:

For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?

Related Questions